Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutants

J Biol Chem. 2022 Dec;298(12):102565. doi: 10.1016/j.jbc.2022.102565. Epub 2022 Oct 5.

Abstract

α-synuclein (αS) is the key component of synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies, and multiple system atrophy. αS was first linked to PD through the identification of point mutations in the SNCA gene, causing single amino acid substitutions within αS and familial autosomal dominant forms of PD that profoundly accelerated disease onset by up to several decades. At least eight single-point mutations linked to familial PD (A30G/P, E46K, H50Q, G51D, and A53T/E/V) are located in proximity of the region preceding the non-β amyloid component (preNAC) region, strongly implicating its pathogenic role in αS-mediated cytotoxicity. Furthermore, lipids are known to be important for native αS function, where they play a key role in the regulation of synaptic vesicle docking to presynaptic membranes and dopamine transmission. However, the role of lipids in the function of mutant αS is unclear. Here, we studied αS aggregation properties of WT αS and five of the most predominant single-point missense mutants associated with early onset PD in the presence of anionic 1,2-dimyristoyl-sn-glycero-3-phospho-l-serine lipid vesicles. Our results highlight significant differences between aggregation rates, the number of aggregates produced, and overall fibril morphologies of WT αS and the A30P, E46K, H50Q, G51D, and A53T missense mutants in the presence of lipid vesicles. These findings have important implications regarding the interplay between the lipids required for αS function and the individual point mutations known to accelerate PD and related diseases.

Keywords: amyloid aggregation; early onset Parkinson’s disease; lipid vesicles; peptide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Gene Expression
  • Humans
  • Lipids
  • Mutation, Missense
  • Parkinson Disease* / metabolism
  • Point Mutation
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • Lipids